Delving into the Latest Updates on Shanghai LaNova Medicines Research and Development Co Ltd with Synapse

Overview

Basic Info

Introduction

Shanghai LaNova Medicines Research and Development Co Ltd., rooted in China yet serving the global market, is an innovative biopharmaceutical company in the clinical stage established by veterans of the industry. Since its inception, the firm has adhered to a mission of "respecting life and dedicating to innovation." It aspires to develop high-quality pharmaceuticals that address the needs of patients, guided by the core values of excellence, perseverance, integrity, and collaboration. The company concentrates its efforts on unmet medical needs within the realms of oncology immunotherapy and the tumor microenvironment, focusing on the research and development of biologic drugs that are either first-in-class or best-in-class with significant development potential.

Tags

Neoplasms

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	2

Top 5 Target	Count

NaPi-2b(Sodium-dependent phosphate transport protein 2B)	1
IL-13Rα2 x Tubulin	1

I期剂量递增主要目的： 1）评估LM-061片剂在晚期实体瘤患者中的安全性和耐受性； 2）确定LM-061片剂在晚期实体瘤患者中的剂量限制性毒性（DLT）和最大耐受剂量（MTD）； 3）确定II期推荐剂量（RP2D）。次要目的： 1）评估LM-061片剂在晚期实体瘤患者中的药代动力学特征； 2）评估LM-061片剂在晚期实体瘤患者中的初步抗肿瘤活性； II期剂量扩展主要目的：评估LM-061片剂在c-MET异常的EGFR-TKI耐药的非小细胞肺癌、肺肉瘤样腺癌、乳头状肾细胞癌、转移或局部晚期不可切的胃腺癌等患者中的抗肿瘤活性；次要目的： 1）评估LM-061片剂在c-MET异常的EGFR-TKI耐药的非小细胞肺癌、肺肉瘤样腺癌、乳头状肾细胞癌、转移或局部晚期不可切的胃腺癌等患者中的安全性和耐受性； 2）评估LM-061片剂在c-MET异常的EGFR-TKI耐药的非小细胞肺癌、肺肉瘤样腺癌、乳头状肾细胞癌、转移或局部晚期不可切的胃腺癌等患者中的药代动力学特征。

[Translation]

Phase I dose escalation Main objectives: 1) Evaluate the safety and tolerability of LM-061 tablets in patients with advanced solid tumors; 2) Determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of LM-061 tablets in patients with advanced solid tumors; 3) Determine the Phase II recommended dose (RP2D). Secondary objectives: 1) Evaluate the pharmacokinetic characteristics of LM-061 tablets in patients with advanced solid tumors; 2) Evaluate the preliminary antitumor activity of LM-061 tablets in patients with advanced solid tumors; Phase II dose expansion Primary objectives: Evaluate the antitumor activity of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.; Secondary objectives: 1) Evaluate the safety and tolerability of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.; 2) Evaluate the pharmacokinetic characteristics of LM-061 tablets in patients with c-MET abnormal EGFR-TKI-resistant non-small cell lung cancer, pulmonary sarcomatoid adenocarcinoma, papillary renal cell carcinoma, metastatic or locally advanced unresectable gastric adenocarcinoma, etc.

Start Date20 May 2021

Sponsor / Collaborator

Shanghai LaNova Medicines Research and Development Co Ltd

100 Clinical Results associated with Shanghai LaNova Medicines Research and Development Co Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai LaNova Medicines Research and Development Co Ltd

Login to view more data

100 Deals associated with Shanghai LaNova Medicines Research and Development Co Ltd

Login to view more data

100 Translational Medicine associated with Shanghai LaNova Medicines Research and Development Co Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LM-306 ( IL-13Rα2 x Tubulin )	Neoplasms More	Preclinical
LM-317 ( NaPi-2b )	Solid tumor More	Preclinical
LM-102 ( CLDN18.2 )	Solid tumor More	Discontinued
LM-061 ( c-Met )	Advanced Malignant Solid Neoplasm More	Discontinued